EGFR mutation in non-small cell lung cancer (NSCLC), RET mutation in medullary thyroid carcinoma, ALK translocation and ROS1 translocation in NSCLC and HER2 amplification in breast cancer have been reported and therapies have been established. This evidence concerns the gene ERBB2 and breast cancer.